Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,400
Employees6,400
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,400
Employees6,400

VRTX Key Statistics

Market cap
130.56B
Market cap130.56B
Price-Earnings ratio
29.71
Price-Earnings ratio29.71
Dividend yield
Dividend yield
Average volume
1.05M
Average volume1.05M
High today
$525.97
High today$525.97
Low today
$508.14
Low today$508.14
Open price
$522.08
Open price$522.08
Volume
1.36M
Volume1.36M
52 Week high
$560.25
52 Week high$560.25
52 Week low
$374.17
52 Week low$374.17

Stock Snapshot

The current Vertex Pharmaceuticals(VRTX) stock price is $517.30, with a market capitalization of 130.56B. The stock trades at a price-to-earnings (P/E) ratio of 29.71.

On 2026-09-22, Vertex Pharmaceuticals(VRTX) stock moved within a range of $508.14 to $525.97. With shares now at $517.30, the stock is trading +1.8% above its intraday low and -1.6% below the session's peak.

Trading activity shows a volume of 1.36M, compared to an average daily volume of 1.05M.

The stock's 52-week range extends from a low of $374.17 to a high of $560.25.

The stock's 52-week range extends from a low of $374.17 to a high of $560.25.

VRTX News

Investor's Business Daily 5h
The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Technology The Surprise That Sent Vertex — And Its Chief Rival — Soaring Licensing Vertex stock popped Tuesday — while shares of rival Maze Therapeutics (MAZE)...

The Surprise That Sent Vertex — And Its Chief Rival — Soaring
TipRanks 8h
Maze jumps 25% to $27.99 after Vertex kidney disease data

10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...

TipRanks 10h
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidne...

Analyst ratings

77%

of 35 ratings
Buy
77.1%
Hold
17.1%
Sell
5.7%

More VRTX News

Fortune 4d
Vertex Pharmaceuticals Q1 2026 Earnings Call Transcript - Fortune

...

Vertex Pharmaceuticals Q1 2026 Earnings Call Transcript - Fortune
Nasdaq 4d
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

Key Points Vertex Pharmaceuticals has declined meaningfully from its most recent high. The company has several catalysts that could jolt the stock over the ne...

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.